A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.
about
Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeysTherapeutic drug monitoring of immunosuppressant drugs.A review of interleukin-2 receptor antagonists in solid organ transplantation.Current treatment practice in immunosuppression.Use of basiliximab and daclizumab in kidney transplantation.Daclizumab induction in solid organ transplantation.The role of basiliximab induction therapy in organ transplantation.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesTwo doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Drug Development of Therapeutic Monoclonal Antibodies.A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis.Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation.A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tranEffect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study.Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.Immunogenicity screening in protein drug development.Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
P2860
Q28365417-3DA7BF8A-6AFD-48A8-8811-AB63CFE760E5Q33610775-B956BDB5-F2CD-44D3-B404-F9855930C9F0Q33747153-496EBBC7-1C31-47A5-B36E-CDE504CC3421Q34181796-8590108C-4D44-4B6B-A1A6-CEF06CD3E09EQ34253750-FB0A3D56-0B9E-491D-931E-54978F326AB1Q35779394-CEF6648E-0521-4ED0-A0FF-CB1887FC222BQ36675465-B0B9EB85-7E00-4614-901D-F1F0EBA445B3Q36724093-F883A2D2-D55E-43F4-ACF4-6828511E3485Q37273477-AA3480CE-EA99-489E-A2C1-CA23ECA26B2DQ37496388-9A885D1B-45F5-4E20-AB7F-0151777B4E65Q38876360-CC23F4EE-A173-48F3-B2B8-F82C59529ECEQ40794894-28F5E1F0-4CAC-4371-B41E-E71FC60228DDQ43071206-364F96B1-6900-42E8-832D-35EDFB7F84F5Q43975358-6EB04E71-0B00-494F-84FE-976598538E2EQ44048428-C2DAD173-57EA-4058-B9EA-9CF0857C3E13Q44844488-CE83F118-B0C2-4C86-93AD-8861BD46069CQ45042010-FACB70FD-BB9F-4DCE-8218-61050C87A669Q46556711-329CCA90-FC25-4E17-A89B-FBA3B7102C4AQ49168236-A36B2B07-3C57-490E-AE59-28BDD25687B5Q53449172-C2579192-6E3F-4E42-9C11-2AB20ECCD2E5
P2860
A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
A phase I trial of humanized a ...... body in renal transplantation.
@en
A phase I trial of humanized a ...... body in renal transplantation.
@nl
type
label
A phase I trial of humanized a ...... body in renal transplantation.
@en
A phase I trial of humanized a ...... body in renal transplantation.
@nl
prefLabel
A phase I trial of humanized a ...... body in renal transplantation.
@en
A phase I trial of humanized a ...... body in renal transplantation.
@nl
P2093
P921
P1433
P1476
A phase I trial of humanized a ...... body in renal transplantation.
@en
P2093
Birnbaum J
Nieforth K
Vincenti F
P356
10.1097/00007890-199701150-00007
P577
1997-01-01T00:00:00Z